


REMARKS

After entry of the amendment, claims 2-5, 15, 20 and 21 will remain pending. In the Office Action dated June 5, 2001, the Examiner allowed claim 24. Applicants have amended claims 2-5, 15, and 20 to be dependent on allowed claim 24, and have cancelled claim 1, 16, 22 and 23. After entry of these amendments, the claims will be in condition for allowance.

Respectfully submitted,




Sherry M. Knowles
Reg. No. 33,052

King & Spalding
191 Peachtree St.
Atlanta, Georgia 30303
404-572-3541
404-572-5145 (fax)

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Amendment and Response to Office Action, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Stephanie D. Adams

December 5, 2001



THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 11 2002
TECH CENTER 1600/2600

Applicants: **Manolagas et al.**

Serial No.: **09/413,785**

Group Art Unit: **1632**

Filed: **October 07, 1999**

Examiner: **Baker**

Title: **METHODS OF SCREENING FOR APOPTOSIS-CONTROLLING AGENTS FOR BONE ANABOLIC THERAPIES AND USES THEREOF**

Marked-Up Version of Claims

2. (twice amended) The method of claim [1] 24, wherein said bone-containing host is osteopenic.
3. (twice amended) The method of claim [1] 24 wherein said bone-containing host is selected from the group consisting of a bone-containing host currently being treated with one or more glucocorticoid compounds and a bone-containing host experiencing adverse bone effects resulting from contact with one or more glucocorticoid compounds.
4. (twice amended) The method of claim [1] 24, wherein said administration is selected from the group consisting of systemic, oral, intravenous, nasal spray and inhalation.
5. (twice amended) The method of claim [1] 24, wherein said parathyroid hormone fragment is human parathyroid fragment [hPHT(1-34)] (1-34).
15. (amended) The method of claim [1] 24, wherein said host is a human.
20. (amended) The method of claim [1] 24, wherein said parathyroid fragment is a bovine parathyroid fragment [bPTH(1-34)] (1-34).
21. (amended) The method of claim [1] 24, wherein the parathyroid hormone is administered in an intermittent fashion.